SecBot SecBot
8-K ·Filed Jul 28, 2026

ALKS

Alkermes plc.
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC0001193125-26-318844
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The headline EPS miss and wider GAAP loss guidance are likely to pressure the stock near-term, but the maintained revenue/adjusted EBITDA guidance and strong LUMRYZ launch provide a floor. Watch for the Q3 2026 trajectory of LUMRYZ and any updates on the alixorexton phase 2 idiopathic hypersomnia data expected by year-end.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$50.50
T+0 close · Jul 28, 2026 · via day close
Latest settled
−13.90%
T+60 · $43.48
Vs SPY
−18.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $50.50entry
  2. T+1 · 4mo ago −4.28%α −2.74% · $48.34
  3. T+5 · 4mo ago −1.92%α −4.19% · $49.53
  4. T+20 · 3mo ago −2.55%α −5.94% · $49.21
  5. T+60 · 27d ago −13.90%α −18.25% · $43.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alkermes reported Q2 2026 revenue of $496.0M (+27% YoY), driven by the Avadel acquisition adding LUMRYZ ($96.6M). GAAP net income was $0.5M ($0.00 EPS), a sharp miss vs consensus of $0.29, due to acquisition-related costs and a $26.4M CVR fair-value charge. Full-year guidance was maintained for revenue and adjusted EBITDA, but GAAP net loss guidance was widened to ($95M)-($115M) from ($70M)-($90M) due to the CVR charge. The CEO transition to Blair Jackson on August 1 is a neutral event. The stock will likely trade on the EPS miss and wider GAAP loss, offset by solid LUMRYZ uptake and maintained core guidance.

Key Financial Metrics

EPS
$0.00
est $0.29 · -100.0%
Revenue
$496.0M
est $457.4M · +8.4% · +27.0% YoY
Rating
miss
Guidance
$1.73B-$1.84B
maintained

Key Facts

  • Q2 2026 total revenue $496.0M, up 27% YoY from $390.7M
  • GAAP net income $0.5M ($0.00 diluted EPS) vs consensus $0.29, a 100% miss
  • LUMRYZ contributed $96.6M in its first full quarter post-Avadel acquisition
  • Full-year 2026 revenue guidance maintained at $1.73B-$1.84B; adjusted EBITDA maintained at $370M-$410M
  • GAAP net loss guidance widened to ($95M)-($115M) from ($70M)-($90M) due to a $26.4M CVR fair-value charge
  • Blair Jackson to become CEO on August 1, 2026; Richard Pops remains Chairman
  • Cash and investments grew to $691.6M from $538.2M at Q1 2026 end

Financial Impact

GAAP EPS miss of $0.29 vs consensus; GAAP net loss guidance widened by ~$25M at midpoint

epsgaap net incomegaap net loss guidance

Risk Factors

  • GAAP net loss guidance widened due to non-cash CVR charge, which may spook momentum investors
  • Integration of Avadel and LUMRYZ commercial execution remain key execution risks
  • CEO transition could introduce near-term organizational uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-318844
Document: alks-20260728.htm0001193125-26-318844
Document: alks-ex99_2.htm0001193125-26-318844
Document: 0001193125-26-318844-index-headers.html0001193125-26-318844
Document: 0001193125-26-318844-index.html0001193125-26-318844
Document: 0001193125-26-318844.txt0001193125-26-318844
8-K Data (Synthetic)0001193125-26-318844

US Market Status

Market Closed · Opens Wed (10h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 28, 2026